Promising First Results With DNA Editing to Lower LDL
The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.
Stay updated with breaking news from Lipids. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.
Plasma ceramides and sphingomyelins with palmitic acid were linked to a 34% and 37% increased risk of sudden cardiac death (SCD) per higher SD of log sphingolipid levels, respectively.
For 1 in 4 patients with primary biliary cholangitis (PBC) who received the investigational PPAR-delta agonist, alkaline phosphatase levels normalized.
'Up to half of RA patients in the United States use long-term glucocorticoids despite previous work suggesting they increase MACE in a dose-dependent way.'
In two studies run in parallel, testing different strategies, automatic referral to a pharmacist was superior to EHR alerts for increasing statin prescriptions for at-risk patients.